Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study.

Molleston JP, Fontana RJ, Lopez MJ, Kleiner DE, Gu J, Chalasani N; Drug-Induced Liver Injury Network.

J Pediatr Gastroenterol Nutr. 2011 Aug;53(2):182-9. doi: 10.1097/MPG.0b013e31821d6cfd.

2.

Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study.

Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H, Gu J, Serrano J; United States Drug Induced Liver Injury Network.

Gastroenterology. 2015 Jun;148(7):1340-52.e7. doi: 10.1053/j.gastro.2015.03.006. Epub 2015 Mar 6.

3.

Drug-induced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience.

Ghabril M, Fontana R, Rockey D, Jiezhun G, Chalasani N.

J Clin Gastroenterol. 2013 Jul;47(6):553-8. doi: 10.1097/MCG.0b013e318276bf00.

4.

Drug-induced liver injury.

Leise MD, Poterucha JJ, Talwalkar JA.

Mayo Clin Proc. 2014 Jan;89(1):95-106. doi: 10.1016/j.mayocp.2013.09.016. Review.

PMID:
24388027
5.

Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.

Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J; DILIN Study Group.

Drug Saf. 2009;32(1):55-68. doi: 10.2165/00002018-200932010-00005.

6.

Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury.

Fontana RJ, Hayashi PH, Barnhart H, Kleiner DE, Reddy KR, Chalasani N, Lee WM, Stolz A, Phillips T, Serrano J, Watkins PB; DILIN Investigators.

Am J Gastroenterol. 2015 Oct;110(10):1450-9. doi: 10.1038/ajg.2015.283. Epub 2015 Sep 8.

PMID:
26346867
7.

Clinical and histologic features of azithromycin-induced liver injury.

Martinez MA, Vuppalanchi R, Fontana RJ, Stolz A, Kleiner DE, Hayashi PH, Gu J, Hoofnagle JH, Chalasani N.

Clin Gastroenterol Hepatol. 2015 Feb;13(2):369-376.e3. doi: 10.1016/j.cgh.2014.07.054. Epub 2014 Aug 9.

8.

An update on drug induced liver injury.

Rangnekar AS, Fontana RJ.

Minerva Gastroenterol Dietol. 2011 Jun;57(2):213-29. Review.

PMID:
21587150
9.

Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.

Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, Serrano J, Lee WM, Chalasani N, Stolz A, Davern T, Talwakar JA; DILIN Network.

Gastroenterology. 2014 Jul;147(1):96-108.e4. doi: 10.1053/j.gastro.2014.03.045. Epub 2014 Mar 27.

10.

Serum proteomic profiling in patients with drug-induced liver injury.

Bell LN, Vuppalanchi R, Watkins PB, Bonkovsky HL, Serrano J, Fontana RJ, Wang M, Rochon J, Chalasani N; US Drug-Induced Liver Injury Network (DILIN) Research Group.

Aliment Pharmacol Ther. 2012 Mar;35(5):600-12.

11.

Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.

Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug Induced Liver Injury Network (DILIN).

Gastroenterology. 2008 Dec;135(6):1924-34, 1934.e1-4. doi: 10.1053/j.gastro.2008.09.011. Epub 2008 Sep 17.

12.

Clinical and histopathologic features of fluoroquinolone-induced liver injury.

Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, Hayashi PH; DILIN Research Group.

Clin Gastroenterol Hepatol. 2011 Jun;9(6):517-523.e3. doi: 10.1016/j.cgh.2011.02.019. Epub 2011 Feb 26.

13.

Drug-induced liver injury in hospitalized patients with notably elevated alanine aminotransferase.

Xu HM, Chen Y, Xu J, Zhou Q.

World J Gastroenterol. 2012 Nov 7;18(41):5972-8. doi: 10.3748/wjg.v18.i41.5972.

14.

Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation.

Sembera S, Lammert C, Talwalkar JA, Sanderson SO, Poterucha JJ, Hay JE, Wiesner RH, Gores GJ, Rosen CB, Heimbach JK, Charlton MR.

Liver Transpl. 2012 Jul;18(7):803-10. doi: 10.1002/lt.23424.

15.

[Clinical and pathological features in 138 cases of drug-induced liver injury].

Lai RT, Wang H, Gui HL, Ye MZ, Dai WJ, Xiang XG, Zhao GD, Wang WJ, Xie Q.

Zhonghua Gan Zang Bing Za Zhi. 2012 Mar;20(3):185-9. doi: 10.3760/cma.j.issn.1007-3418.2012.03.009. Chinese.

PMID:
22475136
16.

Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.

Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M; US Drug-Induced Liver Injury Network.

Clin Gastroenterol Hepatol. 2013 May;11(5):558-564.e3. doi: 10.1016/j.cgh.2012.12.025. Epub 2013 Jan 17. Review.

17.

Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents.

Devarbhavi H, Karanth D, Prasanna KS, Adarsh CK, Patil M.

Hepatology. 2011 Oct;54(4):1344-50. doi: 10.1002/hep.24527. Epub 2011 Sep 6.

PMID:
21735470
18.

Idiosyncratic drug-induced liver injury: an overview.

Hussaini SH, Farrington EA.

Expert Opin Drug Saf. 2007 Nov;6(6):673-84. Review.

PMID:
17967156
19.

Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network.

Russo MW, Hoofnagle JH, Gu J, Fontana RJ, Barnhart H, Kleiner DE, Chalasani N, Bonkovsky HL.

Hepatology. 2014 Aug;60(2):679-86. doi: 10.1002/hep.27157. Epub 2014 May 13.

20.

Risk of drug-induced liver injury from tumor necrosis factor antagonists.

Björnsson ES, Gunnarsson BI, Gröndal G, Jonasson JG, Einarsdottir R, Ludviksson BR, Gudbjörnsson B, Olafsson S.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):602-8. doi: 10.1016/j.cgh.2014.07.062. Epub 2014 Aug 15.

PMID:
25131534
Items per page

Supplemental Content

Write to the Help Desk